SG11202108837WA - Fcmr-binding molecules and uses thereof - Google Patents

Fcmr-binding molecules and uses thereof

Info

Publication number
SG11202108837WA
SG11202108837WA SG11202108837WA SG11202108837WA SG11202108837WA SG 11202108837W A SG11202108837W A SG 11202108837WA SG 11202108837W A SG11202108837W A SG 11202108837WA SG 11202108837W A SG11202108837W A SG 11202108837WA SG 11202108837W A SG11202108837W A SG 11202108837WA
Authority
SG
Singapore
Prior art keywords
fcmr
binding molecules
molecules
binding
Prior art date
Application number
SG11202108837WA
Other languages
English (en)
Inventor
Richard Brokx
Jacqueline M Mason
Mark R Bray
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SG11202108837WA publication Critical patent/SG11202108837WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202108837WA 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof SG11202108837WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806237P 2019-02-15 2019-02-15
PCT/CA2020/050195 WO2020163962A1 (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11202108837WA true SG11202108837WA (en) 2021-09-29

Family

ID=72043773

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108837WA SG11202108837WA (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Country Status (14)

Country Link
US (1) US12286476B2 (https=)
EP (1) EP3924388A4 (https=)
JP (1) JP2022520817A (https=)
KR (1) KR20210139273A (https=)
CN (1) CN113993895A (https=)
AU (1) AU2020222408A1 (https=)
BR (1) BR112021016102A2 (https=)
CA (1) CA3130225A1 (https=)
EA (1) EA202192254A1 (https=)
IL (1) IL285585A (https=)
MX (1) MX2021009767A (https=)
SG (1) SG11202108837WA (https=)
TW (1) TWI857009B (https=)
WO (1) WO2020163962A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
EP2970451A1 (en) * 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9493561B2 (en) * 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
US20180201676A1 (en) 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
ES2690420T3 (es) * 2015-05-28 2018-11-20 Universität Zu Köln Receptor de antígeno quimérico anti-toso y su uso
WO2018119425A2 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Also Published As

Publication number Publication date
EP3924388A1 (en) 2021-12-22
BR112021016102A2 (pt) 2021-11-09
US12286476B2 (en) 2025-04-29
EP3924388A4 (en) 2023-02-15
JP2022520817A (ja) 2022-04-01
EA202192254A1 (ru) 2021-11-29
CA3130225A1 (en) 2020-08-20
TWI857009B (zh) 2024-10-01
AU2020222408A1 (en) 2021-09-09
MX2021009767A (es) 2021-11-17
US20220089725A1 (en) 2022-03-24
KR20210139273A (ko) 2021-11-22
TW202035461A (zh) 2020-10-01
WO2020163962A1 (en) 2020-08-20
IL285585A (en) 2021-09-30
CN113993895A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
ZA202001113B (en) Anti-cd137 molecules and use thereof
SG11202100935TA (en) Collagen-localized immunomodulatory molecules and methods thereof
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
PL3601367T3 (pl) Cząsteczki chimeryczne i ich zastosowania
IL267925B (en) hsd17b13 variants and their uses
IL285177A (en) compounds and their use
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
IL287765A (en) TIGIT and FDI-1/TIGIT binding molecules
EP3265575A4 (en) Cd20 binding molecules and uses thereof
IL278019A (en) trans splicing molecules
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
ZA202105847B (en) Mtroc modulators and uses thereof
IL284781A (en) LILRB3 binding molecules and uses thereof
IL278832A (en) Improved molecules that bind 41GP
SG11202006459XA (en) Proteinaceous molecules and uses therefor
IL287503A (en) Thio-semicarbazide compounds and their use
IL284764A (en) compounds and their uses
EP3573611A4 (en) AMIDE COMPOUNDS AND USES THEREOF
IL285585A (en) fcmr-binding molecules and their uses
IL311510A (en) D3 binding molecules and uses thereof
IL280369A (en) Myokines and their uses
EP4081255A4 (en) ANTI-CSF1R MOLECULES AND USES THEREOF
HK40068201A (en) Fcmr-binding molecules and uses thereof